GeNeuro SA has signed a unique partnership with Servier. The French pharmaceutical giant have bought an option for €38M on the marketing rights outside the United States and Japan for a treatment against multiple sclerosis. Could GeNeuro become the next Merck-Serono?
This amount will allow the Swiss company to continue the clinical development of this molecule. Servier will also cover the costs of additional development and testing, and royalties up to €328M, if the drug gets to the market.
Multiple sclerosis (MS) is an autoimmune and neurodegenerative disease affecting the brain and spinal cord. 2.3 million people are affected by the disease in the world and its market was valued at €11,4 billion in 2013.
Over the last decade, partnerships in the life sciences between a startup and a large group on such amounts can be counted on the fingers of one hand. GeNeuro therapy is particularly promising. Current treatments against multiple sclerosis focus on the patient’s immune system while this molecule acts directly on the cause of the disease.